Project Details
Description
A Non-Randomized, Open Label, Multi-Center, Phase I/II study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Lymphoma
| Status | Finished |
|---|---|
| Effective start/end date | 12/19/17 → 12/18/22 |
Funding
- THE CHILDREN'S HOSPITAL OF PHILADELPHIA
- BAYER HEALTHCARE PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.